文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

抗癌纳米药物:肿瘤免疫治疗的革命。

Anti-Cancer Nanomedicines: A Revolution of Tumor Immunotherapy.

机构信息

Department of General Surgery, Zhuhai People's Hospital, Zhuhai Hospital Affiliated with Jinan University, Jinan University, Zhuhai, China.

Zhuhai Interventional Medical Center, Zhuhai Precision Medical Center, Zhuhai People's Hospital, Zhuhai Hospital Affiliated with Jinan University, Jinan University, Zhuhai, China.

出版信息

Front Immunol. 2020 Dec 21;11:601497. doi: 10.3389/fimmu.2020.601497. eCollection 2020.


DOI:10.3389/fimmu.2020.601497
PMID:33408716
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7779686/
Abstract

Immunotherapies have been accelerating the development of anti-cancer clinical treatment, but its low objective responses and severe off-target immune-related adverse events (irAEs) limit the range of application. Strategies to remove these obstacles primarily focus on the combination of different therapies and the exploitation of new immunotherapeutic agents. Nanomedicine potentiates the effects of activating immune cells selectively and reversing tumor induced immune deficiency microenvironment through multiple mechanisms. In the last decade, a variety of nano-enabled tumor immunotherapies was under clinical investigation. As time goes by, the advantages of nanomedicine are increasingly prominent. With the continuous development of nanotechnology, nanomedicine will offer more distinctive perspectives in imaging diagnosis and treatment of tumors. In this Review, we wish to provide an overview of tumor immunotherapy and the mechanisms of nanomaterials that aim to enhance the efficacy of tumor immunotherapy under development or in clinic treatment.

摘要

免疫疗法一直在加速抗肿瘤临床治疗的发展,但它的客观反应率低和严重的脱靶免疫相关不良事件(irAEs)限制了其应用范围。消除这些障碍的策略主要集中在不同疗法的联合和新免疫治疗药物的开发上。纳米医学通过多种机制增强选择性激活免疫细胞和逆转肿瘤诱导的免疫缺陷微环境的效果。在过去的十年中,多种基于纳米技术的肿瘤免疫疗法正在进行临床研究。随着时间的推移,纳米医学的优势越来越明显。随着纳米技术的不断发展,纳米医学将在肿瘤的成像诊断和治疗方面提供更独特的视角。在这篇综述中,我们希望概述肿瘤免疫疗法和旨在提高正在开发或临床治疗中的肿瘤免疫疗法疗效的纳米材料的机制。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/948d/7779686/c2317b26fe3a/fimmu-11-601497-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/948d/7779686/103199b34c6e/fimmu-11-601497-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/948d/7779686/a6180c50ca2f/fimmu-11-601497-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/948d/7779686/719254723cf4/fimmu-11-601497-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/948d/7779686/d03fcd9972ba/fimmu-11-601497-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/948d/7779686/c2317b26fe3a/fimmu-11-601497-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/948d/7779686/103199b34c6e/fimmu-11-601497-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/948d/7779686/a6180c50ca2f/fimmu-11-601497-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/948d/7779686/719254723cf4/fimmu-11-601497-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/948d/7779686/d03fcd9972ba/fimmu-11-601497-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/948d/7779686/c2317b26fe3a/fimmu-11-601497-g005.jpg

相似文献

[1]
Anti-Cancer Nanomedicines: A Revolution of Tumor Immunotherapy.

Front Immunol. 2020

[2]
Combining Nanomedicine and Immunotherapy.

Acc Chem Res. 2019-5-23

[3]
Tumor-Targeted Nanomedicine for Immunotherapy.

Acc Chem Res. 2020-12-15

[4]
Regulation of cancer-immunity cycle and tumor microenvironment by nanobiomaterials to enhance tumor immunotherapy.

Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2020-7

[5]
Molecular and nanoengineering approaches towards activatable cancer immunotherapy.

Chem Soc Rev. 2020-7-6

[6]
Nanoparticle-Based Nanomedicines to Promote Cancer Immunotherapy: Recent Advances and Future Directions.

Small. 2019-3-25

[7]
Nanomedicines Targeting the Tumor Microenvironment.

Cancer J. 2015

[8]
Nanotechnology synergized immunoengineering for cancer.

Eur J Pharm Biopharm. 2021-6

[9]
Tumor-associated macrophages, nanomedicine and imaging: the axis of success in the future of cancer immunotherapy.

Immunotherapy. 2017-9

[10]
Localized Interleukin-12 for Cancer Immunotherapy.

Front Immunol. 2020

引用本文的文献

[1]
Hybrid Nanogel Drug Delivery Systems: Transforming the Tumor Microenvironment through Tumor Tissue Editing.

Cells. 2024-5-24

[2]
Empagliflozin: a potential anticancer drug.

Discov Oncol. 2023-7-12

[3]
MMP9 and TYROBP affect the survival of circulating tumor cells in clear cell renal cell carcinoma by adapting to tumor immune microenvironment.

Sci Rep. 2023-4-28

[4]
From Natural Sources to Synthetic Derivatives: The Allyl Motif as a Powerful Tool for Fragment-Based Design in Cancer Treatment.

J Med Chem. 2023-3-23

[5]
Nanotechnology-enabled immunogenic cell death for improved cancer immunotherapy.

Int J Pharm. 2023-3-5

[6]
Activation of cancer immunotherapy by nanomedicine.

Front Pharmacol. 2022-12-22

[7]
Editorial: Induced cell senescence as a therapeutic strategy for cancer treatment.

Front Oncol. 2022-12-7

[8]
Engineered nanomaterials trigger abscopal effect in immunotherapy of metastatic cancers.

Front Bioeng Biotechnol. 2022-10-26

[9]
Engineered multifunctional nanocarriers for controlled drug delivery in tumor immunotherapy.

Front Oncol. 2022-10-21

[10]
Physiologically Based Pharmacokinetic Modeling of Nanoparticle Biodistribution: A Review of Existing Models, Simulation Software, and Data Analysis Tools.

Int J Mol Sci. 2022-10-19

本文引用的文献

[1]
Fucoidan-based, tumor-activated nanoplatform for overcoming hypoxia and enhancing photodynamic therapy and antitumor immunity.

Biomaterials. 2020-10

[2]
Interaction Between Virus-Like Particles (VLPs) and Pattern Recognition Receptors (PRRs) From Dendritic Cells (DCs): Toward Better Engineering of VLPs.

Front Immunol. 2020

[3]
High-affinity mutant Interleukin-13 targeted CAR T cells enhance delivery of clickable biodegradable fluorescent nanoparticles to glioblastoma.

Bioact Mater. 2020-5-7

[4]
Nanotechnology and immunoengineering: How nanotechnology can boost CAR-T therapy.

Acta Biomater. 2020-6

[5]
Self-Assembled Multivalent Aptamer Nanoparticles with Potential CAR-like Characteristics Could Activate T Cells and Inhibit Melanoma Growth.

Mol Ther Oncolytics. 2020-3-13

[6]
Recent Progress on the Versatility of Virus-Like Particles.

Vaccines (Basel). 2020-3-20

[7]
Senescence-Induced Vascular Remodeling Creates Therapeutic Vulnerabilities in Pancreas Cancer.

Cell. 2020-3-31

[8]
Nanoparticle interactions with immune cells dominate tumor retention and induce T cell-mediated tumor suppression in models of breast cancer.

Sci Adv. 2020-3-25

[9]
Multifunctional Immunoliposomes Combining Catalase and PD-L1 Antibodies Overcome Tumor Hypoxia and Enhance Immunotherapeutic Effects Against Melanoma.

Int J Nanomedicine. 2020-3-10

[10]
The failure of DAC to induce OCT2 expression and its remission by hemoglobin-based nanocarriers under hypoxia in renal cell carcinoma.

Theranostics. 2020

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索